An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...
The US Court of Appeals for the Federal Circuit on Friday ruled against Regeneron in a closely-watched patent infringement ...
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its ...
Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...